Speaker illustration

Doctor Tomoaki Okada

Kagawa Prefectural Central Hospital, Takamatsu (Japan)

Member of:

EAPCI
Heart Failure Association

Feasibility and safety of early initiation of a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in patients with acute myocardial infarction undergoing primary PCI

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Lipid-Lowering Agents

Session: Pharmacology and Pharmacotherapy ePosters

Thumbnail

This platform is supported by

logo Novo Nordisk